Trials / Completed
CompletedNCT00711269
Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
Randomized, Placebo-controlled, Double-blind, Parallel-group, Confirmatory Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase III Study>
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 460 (actual)
- Sponsor
- Sumitomo Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SM-13496 (lurasidone HCl) | Lurasidone HCl: 40 mg/day |
| DRUG | SM-13496 (lurasidone HCl) | Lurasidone HCl: 80 mg/day |
| DRUG | Placebo | |
| DRUG | Risperidone |
Timeline
- Start date
- 2008-06-27
- Primary completion
- 2010-04-27
- Completion
- 2010-04-27
- First posted
- 2008-07-08
- Last updated
- 2022-04-12
- Results posted
- 2018-10-19
Locations
3 sites across 3 countries: Japan, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT00711269. Inclusion in this directory is not an endorsement.